Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Valeant
Two years after its first FDA review, UCB’s next blockbuster Bimzelx finally crossed the finish line. Supplemental filings for more indications will soon follow as the company forecasts €4bn in peak sales.
When surrogate endpoints are used for accelerated approvals in advance of more compelling functional outcomes, how long should the duration of the confirmatory studies be?
Saunders will oversee the consumer health, pharma and medtech eye health and vision care specialist, returning to where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
Saunders will oversee the eye specialist, returning to the firm where he got his start as a chief executive before earning a reputation as one of industry’s biggest dealmakers.
- OTC, Consumer
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.